MAKO OKAMOTO None;
Yuichi Okumura InnoJin, Inc, Code E (Employment), Johnson & Johnson., FUKOKU Co., Ltd, Code F (Financial Support), InnoJin, Inc, Code P (Patent);
Takenori Inomata Santen Pharmaceutical Co., Ltd, Code C (Consultant/Contractor), InnoJin, Inc., Code E (Employment), : Novartis Pharma KK, Santen Pharmaceutical Co., Ltd., Lion Corporation, SEED Co., Ltd., Johnson & Johnson, Shin Nippon Biomedical Laboratories, Ltd., IBM Japan, Ltd.; , Code F (Financial Support), Renatech Co., Ltd., InnoJin Inc, Code P (Patent);
Maria Miura None;
Keiichi Fujimoto None;
Kunihiko Hirosawa Johnson & Johnson, Code F (Financial Support);
Ken Nagino InnoJin Inc, Code E (Employment);
yuki moroka Johnson & Johnson, Code F (Financial Support);
Fumihiro Hara None;
Shintaro Nakao Kowa Company. Ltd., Mitsubishi Tanabe Pharma Corporation, Alcon Japan, Ltd., Santen Pharmaceutical Co., Ltd., Machida Endoscope Co., Ltd., Wakamoto Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Senju Pharmaceutical Co., Ltd. Nippon Boehringer Ingelheim Co., Ltd., Chugai Pharmaceutical Co., Ltd., Hoya Corporation, and Novartis Pharma K.K., Code F (Financial Support)